EQ — Equillium, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1746466 ·
Last close
$1.21
Market Cap
$99.61M
52W High
$3.54
52W Low
$0.81
ADV30
453,256
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -5,048,000 | -4,583,000 | 55,811,000 | 53,322,000 | 3,132,000 |
| Jun 2026 | 0 | — | -5,155,000 | -4,693,000 | 58,666,000 | 57,164,000 | 2,650,000 |
| Mar 2026 | 0 | — | -5,610,000 | -5,311,000 | 63,083,000 | 61,322,000 | 3,596,000 |
| Dec 2025 | 0 | — | -3,962,000 | -3,775,000 | 31,887,000 | 30,277,000 | 3,290,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,972,000
Investing CF
$-106,000
Financing CF
$65,740,000
CapEx
$-122,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.20
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-226,209,000
Inventory
—
Receivables
$108,000
ST Investments
$0
EBIT TTM
$-19,302,000
Pretax Income TTM
$-18,009,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -23,634,000 | -22,398,000 | 31,887,000 | 3,290,000 | 28,597,000 | -22,746,000 |
| Dec 2024 | 41,095,000 | -8,269,000 | -8,067,000 | 25,604,000 | 6,543,000 | 19,061,000 | -19,026,000 |
| Dec 2023 | 36,084,000 | -14,522,000 | -13,335,000 | 50,530,000 | 27,957,000 | 22,573,000 | -21,783,000 |
| Dec 2022 | 15,759,000 | -39,027,000 | -62,428,000 | 78,421,000 | 46,479,000 | 31,942,000 | -8,733,000 |
TTM Snapshot
Revenues TTM
$1,356,000
NetIncome TTM
$-18,009,000
OpCashFlow TTM
—
Assets (Latest)
$58,666,000
Forward EPS
$-0.23
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ADAG | Adagene Inc. | $99.37M | $1.48 | — |
| IMUX | IMMUNIC, INC. | $100.01M | $7.33 | — |
| HSTC | HST Global, Inc. | $99.00M | $0.70 | — |
| UNCY | Unicycive Therapeutics, Inc. | $101.35M | $3.70 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $101.90M | $0.71 | — |
News headlines (Yahoo Finance, 1h cache)
Equillium Reports Third Quarter 2026 Financial Results and Recent Corporate and Clinical Highlights
2026-11-12 21:05 · Yahoo
Equillium Announces First Subject Dosed in Phase 1 Clinical Trial of EQ504
2026-10-26 12:30 · Yahoo
Equillium Announces Poster Presentation at the 50th Anniversary La Jolla Immunology Conference
2026-10-06 20:05 · Yahoo
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
2026-10-05 20:05 · Yahoo
Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504
2026-09-27 22:01 · Yahoo
Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum
2026-09-16 12:30 · Yahoo
Equillium to Participate in Upcoming Investor Conferences
2026-09-02 12:30 · Yahoo
Equillium Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-13 20:05 · Yahoo
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
2026-05-20 20:05 · Yahoo
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-13 20:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.